Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and Apellis Pharmaceuticals Inc. (NASDAQ:APLS) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Can-Fite BioPharma Ltd.||3.62M||7.22||4.84M||-0.26||0.00|
|Apellis Pharmaceuticals Inc.||N/A||0.00||109.30M||-2.05||0.00|
We can see in table 1 the earnings per share, gross revenue and valuation of Can-Fite BioPharma Ltd. and Apellis Pharmaceuticals Inc.
Table 2 provides us the net margins, return on assets and return on equity of both businesses.
|Net Margins||Return on Equity||Return on Assets|
|Can-Fite BioPharma Ltd.||-133.70%||0%||0%|
|Apellis Pharmaceuticals Inc.||0.00%||-62.1%||-51.4%|
Insider and Institutional Ownership
Roughly 7.76% of Can-Fite BioPharma Ltd. shares are held by institutional investors while 57.6% of Apellis Pharmaceuticals Inc. are owned by institutional investors. Competitively, insiders own roughly 20.7% of Apellis Pharmaceuticals Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Can-Fite BioPharma Ltd.||-3.74%||-0.75%||-3.01%||-5.16%||-6.55%||-13.5%|
|Apellis Pharmaceuticals Inc.||17.21%||12.73%||1.64%||-12.51%||28.52%||-17.14%|
For the past year Can-Fite BioPharma Ltd.’s stock price has smaller decline than Apellis Pharmaceuticals Inc.
Can-Fite BioPharma Ltd. beats on 7 of the 9 factors Apellis Pharmaceuticals Inc.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company’s lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.